Search Weight Loss Topics:

Page 61«..1020..60616263..7080..»

Home » Page 61

Mark C. Markowski, MD, PhD

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps may include. Markowski is an associate professor of oncology at Johns Hopkins University in Baltimore, Maryland.

We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer. It's probably been going on for more than a decade, at least with preclinical studies, and eventually moving into clinical trials. When you treat a patient with metastatic prostate cancer, the backbone of therapy is hormone suppression. We're lowering testosterone levels, trying to get them as low as possible, because testosterone fuels the cancer to grow. When we remove it from the equation, PSA levels go down and that tumor starts to shrink. As a result, patients can live a long time and do very well. But there are also can be a lot of toxicities associated with hormone-based therapies, and so trying to develop non-castrating therapies has been a goal of ours. As I said, when we lower testosterone levels in a patient with metastatic prostate cancer, the cancer will initially respond, but inevitably will become resistantthis is called castration resistance. At the end of the day, even during castration resistance, we think the cancer still wants to signal through the androgen receptor; it still wants to use that testosterone receptor to drive its growth. And it will do so in a number of different ways to get around the testosterone suppression. It can mutate the receptor, it can make more of the receptor, it could splice the receptor so that it doesn't even need testosterone to bind to it anymore, and that cancer will grow. What we've discovered is when you use high-dose testosterone therapy, for lack of a better term, there's just too much electricity flowing through that circuit, and we think we're overwhelming the cancer. By signaling through that testosterone pathway again after potentially years of experiencing a low testosterone environment, this will lead to apoptosis, cell death, and tumor regression. And so, we're trying to take advantage of how it becomes resistant to castration and then really whacking that cancer down by giving it high-dose testosterone therapy that is just too much for the cancer to handle.

We've conducted a number of clinical trials over the years. Initially, we did pilot studies, so very small numbers of patients to test for safety. Weve been treating metastatic prostate cancer with testosterone suppression for the past 80 years. So, when you propose using high-dose testosterone therapies, it can be a bit alarming to move it forward in patients. We did an initial study with etoposide and bipolar androgen therapy. In this trial, it looked like the testosterone therapy by itself worked such that chemotherapy was not necessary. We subsequently moved on to doing different groups of patients, such as patients at different stages of their cancer care. By testing bipolar androgen therapy before and after different novel androgen receptor targeting therapies, we have begun to tease out where bipolar androgen therapy may fit in the treatment paradigm for patients with metastatic prostate cancer? Is it after abiraterone [Zytiga]? Is it after enzalutamide [Xtandi]? After chemo? Where should we employ this kind of testosterone therapy? These questions remain unanswered, but we are getting closer. The largest clinical trial to date was the TRANSFORMER study [NCT02286921], which was a randomized phase 3 study for patients with metastatic castration-resistant prostate cancer after having cancer progression on abiraterone. Patients were randomized to the bipolar androgen vs enzalutamide. The primary end point was radiographic progression-free survival. What we learned from that study was that bipolar androgen therapy certainly works on its own. We can induce clinical responses, PSA decreases, and tumor regression. But when you compare them head-to-head, the results look similar with the enzalutamide. Enzalutamide had similar response rates and a similar radiographic progression-free survival compared to bipolar androgen. It was somewhat disappointing that the primary end point was not met, but when we started to look at secondary end points, we began to better understand that bipolar androgen may prime the tumor to respond to the next line androgen receptor inhibitor. It's not only that the bipolar androgen may work on its own. But it's also that the testosterone therapies may sensitize the patients to other novel androgen receptor targeted therapies. I think when we were designing the TRANSFORMER study, we were looking at testosterone by itself vs enzalutamide by itself. But when we looked at the data, those patients that got testosterone then crossed over to enzalutamide did very well. And there was actually an overall survival benefit when we looked at patients receiving bipolar androgen followed by enzalutamide vs those who just received enzalutamide by itself. That was a secondary end point, so it wouldn't change the standard of care, but at least it was cluing us in to the mechanism here, that it may not just be the bipolar androgen therapy that works, even though it does in certain patients; they do very well. But when they have cancer progression on the testosterone, we really can take advantage of that sensitization effect with next line treatment And so, we may want to prime patients between oral AR-targeted therapies with the testosterone therapy, and I think that was the lesson that we learned from TRANSFORMER.

I think we're still working on that and trying to identify where bipolar androgen therapy would be best suited. We've done a number of trials; like I said, the TRANSFORMER study. We also just completed the COMBAT study [NCT03554317], which was a combination of bipolar androgen with the immune checkpoint inhibitor nivolumab [Opdivo]. The eligibility for the COMBAT study was that patients had to have cancer progression on at least 1 AR-targeted therapy, but there was no limit in number of therapies. And so, we actually got a very heterogeneous population of patients in terms of treatment; some were early phase, early in their clinical disease course, and some were heavily pretreated with a number of oral AR-targeted therapies and even chemotherapies. And so, we got to look at some of the response rates to testosterone therapy in a bunch of different clinical states of prostate cancer. There did not appear to be an advantage of treating early vs later; it seemed like if the testosterone was going to work, it was going to work for however long it was going to work for, irrespective of the number of therapies. So, it's not exactly clear where we should implement it. It seems to work reasonably well wherever we choose to use it. But I think, in a little bit more general terms, mixing in the bipolar androgen after an AR-targeted therapy will sensitize patients to that next line of AR-targeted therapy. We've learned over the years that trying to move from an oral AR-targeted therapy like abiraterone straight to enzalutamide is not the best treatment approach. There should be something in the middle there, whether it's chemotherapy or something else. But that may be a spot where testosterone therapies would become useful to see if we can get you to sensitize to that second AR-targeted therapy.

We're trying to understand that. Conventional wisdom would suggest that the harder you've been targeting that AR-targeted pathway, the more likely you may be to benefit from the testosterone. So, the more pressure you put on the androgen receptor over time, perhaps we can take advantage of giving the bipolar androgen therapy, and that's been our hypothesis. We have not found clear, convincing evidence that the line of AR-targeted therapies will either improve or worsen outcomes. We're looking into that. What we're trying to do now is pool all the patients that we've treated over a number of clinical trials and even off clinical trials to answer this question. If we have 500 to 700 patients with various degrees of prior treatment, we may be able to at least retrospectively get a signal to say, which patients responded best to bipolar androgen. We're trying to figure that out. But I think right now, that's unclear, and we don't have that answer.

That's the million-dollar question right now. We're going over the data from the COMBAT study. The best part about that study is that we took serial biopsies from patients, so we have actual tissue that we can study from before testosterone and during testosterone. We have serial blood draws; we have a lot of time points where we're collecting specimens for patients to try to answer that question. Dr. Laura Sena, Dr. David Sanin, and others have begun to analyze some of that data. I think it's no surprise that when we study the androgen receptor and androgen receptor signaling, we're starting to see a pattern of who's going to respond to bipolar androgen. Its not just in patients who have the highest level of androgen receptor -That doesn't appear to be the case. But the data suggest that those patients that have high signaling through the androgen receptor - so if you can give them a score for androgen signaling, those that had the highest androgen receptor scorehad the best response to testosterone. From a practical perspective, that makes sense; those patients who are heavily dependent on the androgen receptor pathway may see the most benefit using a drug that's clearly hitting the androgen receptor pathway. I think that's what we found so farthat high AR signaling will predict response. We're also finding that bipolar androgen therapy can reduce MYC expression. MYC is a common oncogene in many cancers, not just prostate cancer. We found that those patients who respond deeply to bipolar androgen had very significant declines in MYC protein expression. There are still some pieces to put together there. So I think if I'm going to answer this a little bit more succinctly, patients with tumors that had high AR signaling did better on bipolar androgen, and those that we found had the most robust MYC decrease in protein expression also did very well. The relationship between AR and MYC is there, and we're trying to explore that further.

I think it's received attention. I think people are interested in the topic. The beauty of bipolar androgen is that it's relatively cheap. Injections of testosterone are somewhere in the range of $20 to $30 a month. For cancer treatments, that's remarkably inexpensive. I think there's a cost effectiveness to it. I think it's very safe. And then, in terms of the side effects of bipolar androgen, many of the "side effects are actually positive changes. Hot flashes go away, they have more energy, they get more libido, they can have erections, and this is all during the course of received treatment for metastatic prostate cancer. I think people are interested in it based on the quality-of-life perspective, the cost efficiency of it. But I also think providers need to see concrete data showing that bipolar androgen is superior to whatever cancer treatment that we're comparing it to. I think each trial that we do, we're clearly seeing signal and the treatment seems safe. What we're still trying to identify is what's the right sequence so that we can inform treatment. That kind of parlays into ongoing clinical trials with bipolar androgen. And I think the one trial that I will highlight is the STEP-UP trial [NCT04363164]. This trial involvespatients with metastatic castration-resistant prostate cancer who received prior treatment with abiraterone. They get randomized to 1 of 3 groups. They can go into the enzalutamide-only group, so they go straight from abiraterone to enzalutamide. That was 1 of the control groups in the TRANSFORMER study. And then there are 2 experimental arms. In 1 of these arms, patients get bipolar androgen therapy until progression, and then enzalutamide until progression. The third arm is a kind of flip-flop; patients receive bipolar androgen therapy for a period of time, then enzalutamide, then bipolar androgen and back to enzalutamide. The hope here is that this trial is going to be a more definitive study to really show the benefit of bipolar androgen therapy because TRANSFORMER didn't build that second piece, the enzalutamide treatment, into the primary end point. So if STEP-UP is positive and shows a clear difference vs enzalutamide alone, then I think the way patients with metastatic prostate cancer are treated is going to change. Bipolar androgen will get more attention, and more people are going to do it. I think the other part of this conversation is that there is some concern about providers and patients doing testosterone therapy off label and on their own without clear clinical guidance. It's great to get attention for your work, but we're also a bit concern that providers are just going to do it in patients because testosterone is FDA approved affordable. But we worry about safety and monitoring. How do you follow those patients? It can be a little tricky because we're using testosterone. Testosterone can signal through AR, and those cancers can make more PSA. Well, that rise in PSA may not reflect tumor growth, so do you manage that in patients? It becomes a little bit tricky. We've gotten good experience with managing these patients, like I said, over the past 10 years, sowe kind of know what patterns we're looking for. Whereas if you don't have experience, we just worry about safety. It's a double-edged sword. It's nice to get attention; I think it is getting attention. But we also worry about people going out and doing it without the proper guardrails in place.

As we learn more about mechanism, which we're understanding from the COMBAT study, we're trying to find logical partners to put with bipolar androgen therapy. I think there are 2 directions that we're going in. One is bipolar androgen by itself and the sensitization to other AR therapies story, and I think STEP-UP is going to tell that story. And then there's another direction that is somewhat open endedwhat are logical partners to pair with bipolar androgen? How do we make bipolar androgen therapy work better? Can we figure out a way to keep MYC levels down for longer? Can we pair testosterone with some MYC inhibitor or some suppressor of MYC expression to make it work better? It's possible. Are there other logical pairs of treatments that go with bipolar androgen? Yes, absolutely, and we're trying to figure those out as we go. I think it's a 2-pronged approach. One is the conventional approach, which is STEP-UP. And then as we dig through the data from our prior studies to say what makes sense to pair with bipolar androgen? We are working those out right now.

See the original post here:
Bipolar androgen therapy in prostate cancer: Current evidence and next steps - Urology Times

Read More..

A recent study published in the journal Psychopharmacology shows that men currently using anabolic-androgenic steroids face challenges in accurately recognizing facial expressions of emotion, especially those of anger and disgust. This effect appears to be more pronounced among individuals with steroid dependence.

Anabolic-androgenic steroids, synthetic variations of the male hormone testosterone, are widely known for their use among athletes and bodybuilders to enhance physical performance and muscle mass. Despite their popularity, anabolic-androgenic steroids come with a host of potential side effects, including significant impacts on mental health and cognitive functions.

Prior studies have associated anabolic-androgenic steroids use with increased aggression, anxiety, depression, and personality disorders. Intriguingly, these behavioral changes may stem from impaired social cognitive functions, such as recognizing and interpreting others emotionsa crucial skill for effective non-verbal communication and empathy.

Motivated by the gap in understanding the specific impact of anabolic-androgenic steroids on emotional recognition, researchers conducted this study to better understand the effects of steroid use and dependence on the ability to recognize facial expressions of emotion accurately. They hypothesized that anabolic-androgenic steroid use would correlate with diminished accuracy in emotional recognition, potentially mediated by altered hormone levels.

Our team has previously investigated the role of anabolic steroids in recognizing emotions from biological movement and theory of mind video tasks, so we were interested in how people who use(d) steroids recognize emotions from facial expressions, said study author Morgan Scarth, a postdoctoral researcher at Oslo University Hospital.

We were also interested if fluctuations in hormone levels could explain any differences in emotional recognition abilities. The ability to recognize and respond to other peoples emotions may have implications for social behaviors.

The study cohort comprised 171 adult men engaged in heavy resistance training, divided into two main groups: those who had used anabolic-androgenic steroids (94 participants) and a control group with no history of steroid use (77 participants). The steroid group was further categorized based on current usage status into those currently using steroids (On) and those who had ceased use (Off).

Participants underwent a comprehensive evaluation including emotional recognition tasks, hormone level measurements, and assessments for anabolic-androgenic steroid dependence. Emotional recognition was tested using a computerized task where participants identified emotions from facial expressions. Hormone levels were analyzed from blood samples, focusing on the serum free testosterone index (FTI) among others.

Men who were currently using steroids demonstrated a significantly lower ability to accurately recognize facial expressions of anger and disgust. This indicates that steroid use may impair individuals capacity to interpret these particular negative emotions, which could have implications for social interactions and communication.

The researchers further identified that individuals with a dependence on steroids showed a worse recognition of fear compared to those without such dependence. This suggests that beyond the general effects of steroid use, developing a dependence on these substances might be associated with additional deficits in social cognition.

The researchers did not find evidence that FTI levels significantly mediated the impact of steroid use on the ability to recognize facial expressions of emotion. This indicates that while testosterone levels are altered by steroid use and correlated with changes in emotion recognition, they do not fully explain the observed deficits in recognizing certain emotions.

Men who are currently using anabolic steroids may have a reduced ability to recognize negative facial emotional expressions, specifically anger and disgust, Scarth told PsyPost. This effect does not seem to be explained by fluctuations in the hormone levels measured in the study. Men who had previously used anabolic steroids but have quit did not seem to have the same deficits, suggesting that this effect may be temporary.

However, the study is not without its limitations. The specificity of the sample all male, heavily involved in resistance training, and primarily Norwegian limits the generalizability of the findings to broader populations, including females and those from other cultural backgrounds. Additionally, the cross-sectional design precludes conclusions about causality, and the presence of unmeasured confounding variables could influence the observed relationships.

The study is cross-sectional, so we cannot make any claims that steroid use causes impaired emotion recognition, Scarth explained. Also, we do not account for the specific types of anabolic steroids used, nor the duration of use or how recently steroids were used prior to completing the emotion recognition task, which may have some impact on social cognitive abilities.

Looking ahead, the research team aims to delve deeper into the neurological impacts of anabolic-androgenic steroids, with a particular focus on how these substances affect brain aging and cognitive functions over time. By unraveling the nuanced ways in which synthetic hormones influence our minds and social lives, this line of inquiry holds the promise of informing more effective interventions for those affected by steroid use and dependence.

The research group is continuing to investigate how anabolic steroids impact the brain and cognition, and is particularly interested in the effects of anabolic steroids on brain aging, Scarth said.

The study, Supraphysiological testosterone levels from anabolic steroid use and reduced sensitivity to negative facial expressions in men, was authored by Morgan Scarth, Lisa Evju Hauger, Per Medbe Thorsby, Siri Leknes, Ingunn R Hullstein, Lars T. Westlye, and Astrid Bjrnebekk.

Follow this link:
Steroid use linked to diminished emotional recognition skills in men - PsyPost

Read More..

STEPHEN A. SMITH has undergone a dramatic physical transformation over the last year, after a series of health issues prompted him to make some major changes to his lifestyle. In a recent wide-ranging interview with biologist and 10X Health founder Gary Brecka on his

"That was me a year ago, ladies and gentlemen," he said, over an image of himself before he began his weight loss journey. "Yeah, that was your boy Stephen A. I can't even tell you how bad I was. Nearly 30 percent body fat. A cholesterol level over 300. And .1 point away from being a full-blown diabetic. And that was after I had Covid, which damn near killed me."

"This is a year later," he continued, showing off his visibly leaner appearance. "As you can see, times have changed."

While Smith tends to be a very private person outside of his work as a sports anchor, he felt compelled to share his health journey and be transparent, in the hopes that it will encourage others to take proactive action in their own lives.

Smith revealed that a year after beginning the process of changing his diet and increasing his physical activity, he is no longer pre-diabetic, his blood sugar is normal, and he's gained around 6 pounds of lean muscle.

He also addressed the rumors that his recent weight loss has been aided by the controversial diabetes medication Ozempic, which has become popular as a "diet drug" in wealthy circles.

"I've had people come up to me man, you know, that Ozempic must be good," he said. "I'm like, I didn't take that! I'm doing cardio six days a week, weightlifting five days a week, I take my supplements and vitamins, but I'm not doing that."

He added that his mindset with regards to exercise has also changed dramatically, saying: "I went from being conniving and slick and trying to avoid the gym to being pissed off that I missed going to the gym."

Visit link:
Stephen A. Smith Opens Up About Weight Loss Transformation - Men's Health

Read More..

Everybody was happy except my GI tract

Vicki Webb Pouncey, a 58-year-old breast cancer patient from Melbourne, Florida, tried three of the drugs over the last few years, under the supervision of both her nurse practitioner (who discovered Pouncey was insulin resistant) and her oncologist, who worried her extra weight might drive a recurrence.

She first tried the low-dose pill Rybelsis, but after several weeks had zero results. So she tried Wegovy using a discount coupon for a six-month supply.

On the Wegovy, I lost 40 pounds right away and my numbers all started to improve, she said. Cholesterol, blood sugar, insulin resistance that all looked better. But then the coupon ran out and I couldnt get any more so I went back on the Rybelsis.

Again, her weight loss stalled. So her providers suggested she try Ozempic. Immediately, pounds started to come off again.

I lost weight and my labs looked great, she said. Everybody was happy except my GI tract.

The drugs can have considerable side effects. Ozempic lists the most common as nausea, diarrhea, abdominal pain, vomiting and constipation. Zepbound lists the same plusindigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss and heartburn. It also mentions the potential for kidney failure; gallbladder problems; pancreatitis; low blood sugar; changes in vision and depression.

At first, Pouncey only had nausea and diarrhea a few days after her weekly shot; then it started happening more often.

The drug absolutely diminished her food cravings and her sweet tooth, she said, and she felt healthier, at least for a while. But Ozempic may have been too effective.

There were days when I had to make myself eat, she said. At one point, I think I became malnourished because of all the nausea and diarrhea. But my lab numbers were beautiful so I stayed on it.

After several months, though, the GI issues became a daily ordeal and she started to have pain on her right side. Now, there were only good hours, not good days, she said.

She stopped the Ozempic and went to her doctor about the pain. He ordered a CT scan, thinking shed developed pancreatitis, one of the noted side effects. Instead, the CT scan found metastatic breast cancer in her liver, which led to more scans and more tumors.

The scans also detected nodules on her thyroid, which have yet to be biopsied. The metastatic breast cancer treatment is her primary concern, she said.

She absolutely does not attribute her metastatic recurrence to the weight-loss drugs.

I understand the difference between correlation and causation, she said. The thyroid nodules are the only thing I would associate with it. And it lists that in the risk factors on the label.

Even with the all the suffering, Pouncey said the drugs were beneficial. All told, she lost 80 pounds; her cholesterol, insulin resistance and blood sugar improved dramatically and she was even free of the joint pain caused by her anti-hormone drugs.

Once I got rid of processed sugar and carbs, my joint pain almost resolved itself, she said. And losing the weight took the pressure off my knees.

View original post here:
The new weight-loss drugs and cancer - Fred Hutchinson Cancer Center

Read More..

The Gila monster is a poisonous North American lizard that measures around 50 centimetres and sports a distinctive coat of black and orange scales. This lethargic reptile, which mostly dwells underground and eats just three to four times a year, is the unlikely inspiration for one of pharmas biggest blockbusters: a new generation of weight-loss drugs that has patientsand investorsin a frenzy. Originally made for diabetes, evidence is growing that they also have benefits in diseases of the heart, kidney, liver and beyond.

Since the late 1980s scientists believed that a gut hormone called glucagon-like peptide-1 (GLP-1), which is secreted by the intestines after a meal, could help treat diabetes. GLP-1 increases the production of insulin (a hormone that lowers blood-sugar levels) and reduces the production of glucagon (which increases blood-sugar levels). But GLP-1 is broken down by enzymes in the body very quickly, so it sticks around for only a few minutes. If it were to be used as a drug, therefore, patients would have faced the unwelcome prospect of needing GLP-1 injections every hour.

In 1990 John Eng, a researcher at the Veterans Affairs Medical Centre in The Bronx, discovered that exendin-4, a hormone found in the venom of the Gila monster, was similar to human GLP-1. Crucially, the exendin-4 released after one of the monsters rare meals is more resistant to enzymatic breakdown than GLP-1, staying in its body for hours. It took more than a decade before exenatide, a synthetic version of the lizard hormone, created by Eli Lilly, an American pharma giant, and Amylin Pharmaceuticals, a biotech firm, was approved to treat diabetes in America. This breakthrough spurred other firms to develop more effective and longer-lasting GLP-1 medications as a treatment option for diabetes, beyond injections of insulin.

Scientists had also been aware that GLP-1 had another side-effect: it slowed the rate of gastric emptying, which allows food to stay in the stomach for longer and suppresses appetite. But the potential weight-loss benefits were not seriously pursued at first. It was only in 2021 that Novo Nordisk, a Danish firm, showed data from a clinical trial where overweight or obese patients were put on a weekly dose of its GLP-1-based diabetic drug, semaglutide, which was then being marketed under the name Ozempic, for 68 weeks. The results were dramaticparticipants had lost 15% of their body weight, on average.

The medicines that mimic the GLP-1 hormone then became blockbusters. With close to half of the worlds population expected to be obese or overweight by 2030, according to the World Obesity Federation, demand for these drugs is surgingBloomberg, a data provider, estimates that these medications will hit $80bn in yearly sales by then. The market is projected to grow by 26% per year in the next 5 years, compared with16% per year for oncology drugs and 4% per year for immunology medicines, the two other biggest areas.

So far only three GLP-1 drugs have been approved to treat obese or overweight individuals: liraglutide and semaglutide, developed by Novo; and tirzepatide, made by Lilly. But the market has already attracted a wave of competitors (see chart 1). Bloomberg tracks close to 100 wannabe drugs in the development pipeline. Most new therapies hope to outdo semaglutide and tirzepatide by crafting drugs that are easier to take, cause fewer side-effects or deliver more effective weight loss (see chart 2).

Start with convenience. Both semaglutide and tirzepatide are injections that need to be taken weekly. Stop the dose and most of the weight returns within a year. Amgen, a large American biotech firm, is developing an anti-obesity drug that relies on doses once a month, and hopes the weight-loss effects will last even after treatment ends. AMG133 activates receptors for GLP-1 while blocking receptors of glucose-dependent insulinotropic polypeptide (GIP), a hormone secreted in the small intestine in response to food intake that stimulates the production of both insulin and glucagon. The company is now conducting clinical trials to find out if patients can, over time, be gradually weaned towards smaller doses.

Switching from injections to pills would also make the drugs a lot more tolerable for those who dislike needles. Novo is working on an oral version of semaglutide that works just as well as its jabs. But the pill requires 20 times the amount of the active ingredient as the injection, and must be taken daily. With semaglutide in short supply, Novo has had to push back the oral versions launch. Lilly also has a daily pill that targets GLP-1 receptors called orforglipron in late-stage clinical trials.

Another drawback of GLP-1-based medicines is the nausea and vomiting that frequently accompanies their use. Zealand Pharma, a Danish biotech firm, is developing a drug that is based on a different hormone called amylin, produced in the pancreas along with insulin in response to food intake. But unlike GLP-1, which suppresses appetite, amylin induces satiety, or the feeling of fullness after a meal.

Adam Steesburg, boss of Zealand, says that in most people a hormone called leptin is released from fat tissue that signals to the brain that the body is full. Obese individuals are insensitive to that hormone. Clinical studies have shown that analogues of amylin can make people sensitive to leptin again, helping them to stop eating earlier. Feeling full, rather than lowering appetite, may also reduce the feeling of nausea. Mr Steesburg says that results from early-stage trials suggest that its drug could achieve similar weight loss as GLP-1 drugs, but with less nausea and vomiting.

Besides pesky injections and nausea, a bigger concern is that patients on these drugs do not just shed fat, they also lose lean muscle mass. Some patients drop almost 40% of their body weight in lean mass, a serious concern for older patients. To counter this, companies are trying out, alongside GLP-1 drugs, medicines originally designed to treat muscle atrophy.

Regeneron, an American pharma company, is testing drugs that block myostatin and activin, proteins that inhibit muscle growth in the body. Taken with semaglutide, the combination can potentially boost the quality of weight loss by preserving lean muscle. Similarly, BioAge, a California-based biotech, is testing a drug that activates the apelin receptor that can be taken alongside Lillys tirzepatideApelin, a hormone secreted after exercise that acts on skeletal muscle, the heart and the central nervous system to regulate metabolism and promote muscle regeneration. In obese mice, the combination led to greater weight loss compared to tirzepatide alone, while preserving lean body tissue.

The slimming drugs arent just for shedding pounds. Because obesity is linked to over 200 health issues, including strokes, kidney problems and fatty liver, GLP-1 drugs are proving useful for more than just obesity.

A recent clinical trial by Novo that ran for five years and enrolled more than 17,500 participants found that semaglutide cut the risk of serious heart issues like heart attacks, strokes, or death from heart disease by 20%. Novo believes that the heart benefits of the treatment are not due to weight loss alone, because the reduction in the risk of cardiovascular problems occurred early, before patients lost weight. In March semaglutide was approved by the US Food and Drug Administration for reducing the risk of heart disease in obese or overweight people, the first time a weight-loss medication has been approved for this purpose. Results from another clinical trial have shown that semaglutide reduced the risk of kidney-disease-related events by 24% in patients with type-2 diabetes.

Another weight-loss drug, survodutide, being developed by Boehringer Ingelheim, a German drug company, and Zealand, has shown promising results in being able to treat a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH). This is caused by the build-up of excess fat in the liver and can lead to liver cancer or liver failure. In a recent trial of 295 patients, 83% saw significant improvement in their condition when treated with survodutide, compared with 18% of those on a placebo. Survodutide targets receptors for GLP-1 and glucagon. Waheed Jamal from Boehringer Ingelheim says that there is evidence that glucagon breaks down more fat in the liver compared with GLP-1 and reduces fibrosis (build up of excessive scar tissue in the liver).

While a lot of focus has been on the action of these medicines on improving metabolic health, scientists are now uncovering that these drugs also engage with the brain and immune system, by interacting with GLP-1 receptors in the brain.

Daniel Drucker, a diabetes researcher at Mount Sinai Hospital in Toronto, found that in mice suffering from extensive inflammation throughout the body, GLP-1 drugs reduced the condition, but only when the receptors in the brain werent blocked. When the brain receptors in mice were either blocked or genetically deleted, the anti-inflammatory properties of the drugs were lost. This suggests that the GLP-1 drugs tame inflammation by acting on the brain cells.

For some this suggests that these drugs might be useful for treating brain disorders that are characterised by inflammation, such as Alzheimers disease and Parkinsons disease, both of which are characterised by inflammation in the brain. Since 2021, Novo has been conducting a clinical trial involving more than 1,800 patients to test whether semaglutide helps patients with early stages of Alzheimers. This study is expected to be completed by 2026.

Dr Drucker sees the anti-inflammatory qualities of GLP-1 medications as key to their versatility. He notes that besides Alzheimers and Parkinsons, chronic inflammation is a factor in many complications for people with type-2 diabetes and obesity, and affects organs like the kidneys, heart, blood vessels, and liver. If these drugs eventually help in treating these conditions, Dr Drucker believes that their inflammation-reducing properties could explain part of their success.

The appetite-suppressing effects of these drugs has also raised interest in their ability to curb cravings for other substances. Researchers in Denmark investigated the effect of GLP-1 drugs on people with alcohol-use disorder. In the study of 130 people, they found no difference between patients who used the drugs (alongside therapy) compared with those using a placebo. However there was a reduction in alcohol consumption in obese patients. When the researchers looked at the brain activity of the patients by showing them pictures of alcoholic drinks, for those in the placebo groups the reward centres of their brains lit up. For patients on GLP-1 drugs, the activity of the brain in the areas associated with reward and addiction was attenuated, indicating a direct brain effect. Some researchers are now actively exploring whether the drugs might have an impact on how people use other addictive substances such as tobacco or marijuana.

All of these findings are still early. Developing new drugs is costly and time-consuming. There are steep failure rates. Successes in the lab may not work in people, and results in small groups may not replicate in larger ones. But with the potential to treat dozens of conditions well beyond obesity and diabetes, hope around the new drugs will only grow.

More here:
Could weight-loss drugs eat the world? - The Economist

Read More..

Summary

After losing over 400 pounds, 1000-lb Sisters star Tammy Slaton has been experimenting with the boho fashion aesthetic and posting them on social media. When the series premiered in 2020, Tammy weighed 725 pounds at her heaviest, but she has since gone through an extraordinary weight-loss journey. After a health scare that landed her in the hospital and a medically induced coma, Tammy decided she had to change her life. She checked herself into rehab, where, through diet and exercise, she lost enough weight to qualify for bariatric surgery.

After losing 400 pounds, the 1000-lb Sisters season 5 star is living an entirely different life. Before Tammy lost weight, her mobility was limited, and her size made her a prisoner in her own home. Now, she travels with her family, tries new things, and celebrates new milestones at every turn. Tammy has especially enjoyed experimenting with style and fashion since losing weight, trying on clothes and looks that weren't available to her at her previous size.

In January, Tammy posted a TikTok of herself singing a duet with fellow TikTok creator @Crazyjen1998. In the side-by-side split screen, the women are singing along to a remake of Rachel Platten's "Fight Song." The power anthem is the perfect background tune to the last few years of Tammy's life. Despite the triumph of losing weight, Tammy suffered a tragedy during 1000-lb Sisters season 5, when her husband, Caleb Willingham, sadly passed away from complications due to obesity. She had to fight hard to stay on track with her weight-loss despite being devastated by the loss.

" Looking good girl!! Proud of you."

In January, Tammy posted a TikTok clip of herself showing off her outfit of the day. In the clip, she's wearing a wildly colorful tie-dye top that screams flower power. In a nod to another of Tammy's weight-loss milestones, she's also wearing jeans, which would have been impossible before Tammy lost all of the weight. At her former size, she would never have been able to find a pair of denim jeans. In the clip, Tammy lifts her shirt slightly to show off that her jeans have a zipper and front button closure, as opposed to an elastic waistband.

" You are doing great and you look AMAZING!"

Fans of the 1000-lb Sisters star took to the comment section to offer their support to Tammy. "Looking good girl!! Proud of you," wrote one fan, while another reiterated, "you look amazing!! I love that shirt!!" Though the internet isn't known for kindness in the comment section, the Slatons have always had a great relationship with their supportive fan base. Another fan wrote, "You are doing great and you look AMAZING!"

In a TikTok Tammy posted in July 2023, she's wearing fun rope bracelets and is ready for spring in her floral printed top. The 1000-lb Sisters star is also wearing layered boho chic necklaces, including the treble clef necklace she has often been spotted wearing lately. Her full face of skillfully applied makeup shows how much slimmer Tammy's face is than it used to be before she lost over 400 pounds. There are no comments in the comment section because it's locked, but the clip has over 5,000 likes.

Tammy isn't the only Slaton who has gotten in on the weight-loss action since the show premiered. Her sister and fellow 1000-lb Sisters star, Amy Slaton, has lost over a hundred pounds as well. Additionally, Tammy and Amy's step-brother, Chris Combs, has lost over 150 pounds, while their step-sister, Amanda Halterman, has lost over 300 pounds. Though the Slatons have lost over a thousand combined pounds over the years, they are all still planning and working on losing more weight while inspiring others with their incredible journeys.

Tammy Slaton

Lost 400+ pounds

Diet, exercise, weight loss surgery

Amy Slaton

Lost 125+ pounds

Diet, exercise, weight loss surgery

Chris Combs

Lost 150+ pounds

Diet, exercise, weight loss surgery

Amanda Halterman

Lost 300+ pounds

Weight loss surgery

Misty Slaton

Unknown

Wants weight-loss surgery

In August 2023, Tammy posted a video clip of herself to Instagram, and in the clip, Tammy is singing along with Taylor Swift's "Shake It Off." The lyrics "Haters gonna hate, hate, hate, hate, hate, hate" are intended for the haters in the comment section commenting negatively about Tammy's body since losing weight. Many of the criticisms come from people who point out that Tammy has a lot of extra skin since losing weight, while others want Tammy to fix her teeth. Too many people have forgotten that if they can't say anything nice, it's best to say nothing at all.

" she cant win guys. when she was overweight you hated her and then when she loses weight you make fun of the way her body looks. What is she supposed to do?"

Though some people in the comments still had plenty to say about the extra skin Tammy has since she has lost over 400 pounds. The positive comments far outnumber the negative comments. One Instagram user said it best, writing, "she cant win guys. when she was overweight you hated her and then when she loses weight you make fun of the way her body looks. What is she supposed to do?" The 1000-lb Sisters star is shaking off all the criticism with a smile on her face.

1000-lb Sisters seasons 1-5 can be streamed on MAX and Discovery+.

Sources: Tammy Slaton/TikTok, Tammy Slaton/TickTock, Tammy Slaton/TikTok, Tammy Slaton/Instagram

1000-lb Sisters follows sisters Amy Salton-Halterman and Tammy Slaton in their home in Dixon, Kentucky, covering their daily lives, weight loss attempts, and subsequent weight loss surgery. The show covers such moments as attempts to have children, medical visits, and dramatic emergency room visitations. The family wrestles with supporting their daughters and their weight loss efforts while struggling with their own life troubles.

Continued here:
1000-Lb Sisters: Tammy's Best Hippie Outfits After Extraordinary Weight Loss Milestone (You'll Love Her Boho Clothes) - Screen Rant

Read More..

People who lost weight and gained it back repeatedly a phenomenon commonly called weight cycling that is often associated with yo-yo dieting were significantly more likely to experience negative cardiovascular events like heart attack and stroke, regardless of other cardiac risk factors and average overall weight, according to a study published March 21 in JAMA Network Open.

[1]

Our findings indicate that on a population level, individuals with greater variability in BMI [body mass index] are at higher risk for adverse cardiovascular events as compared to others with less BMI variability, says a coauthor of the study,Zakaria Almuwaqqat, MD, MPH, a hospital medicine doctor and postdoctoral fellow in cardiovascular disease at Emory Healthcare in Atlanta.

[2]

[3]

[4]

[5]

The study used data from two large cohorts, the Million Veteran Program of more than 92,000 U.S. veterans, and 65,000 people from the UK Biobank.

The veteran group had an average age of 57, and 88 percent were men. Ten percent were Hispanic, 24 percent were Black, and 65 percent were white. The average BMI was 30, and BMI measurements were taken multiple times over an average of 10 years. At least three measurements were needed for an individual to be included in the study.

The UK group also had an average age of 57, and 41.5 percent were men. All the subjects were white, and the average BMI was 27 significantly less than the veteran group average.

Weight cycling was measured by averaging the BMI measurements over the course of the study. For example, if one subject had three different BMI measurements of 30, 31, and 32, the average would be 31 and the standard deviation would be 1.

Participants were followed for about four years. During that time, researchers tracked the number of heart attacks, strokes, and deaths due to heart disease.

The researchers found that weight cycling was associated with an increased risk of negative cardiovascular events in all racial and ethnic groups. In the veteran cohort, each 1 standard deviation increase in BMI variability was associated with a 16 percent higher risk of cardiovascular events, which included nonfatal heart attack, stroke, and deaths from heart disease.

In the UK Biobank cohort, each 1 standard deviation increase in BMI variability was associated with an 8 percent higher risk of cardiovascular death.

We have found that the greater change in BMI correlates with a higher risk of adverse cardiovascular events in a dose-dependent manner, says Dr. Almuwaqqat.

Because the study used each subjects individual weight to calculate the standard deviation, it is difficult to pinpoint the exact amount of weight fluctuation that is considered high risk, since it is very patient specific, says Nishant Shah, MD, a cardiologist at Duke Health in Durham, North Carolina, who was not involved in the study.

Instead, consider rapid shifts over a course of time for example, down 20 pounds from baseline and then up 20 pounds from baseline over a six month period to be of more cardiovascular risk than a sustained 20 pound weight loss, according to the study results, he says.

Investigators also found that the associated risk was different depending on race and ethnicity. The association between weight cycling and stroke was stronger in Black participants, and the link between weight cycling and cardiovascular death was higher in white subjects. Because the association wasnt as strong in the UK group, the risks could be influenced by race or sex, the authors noted.

[6]

Its unclear exactly why weight cycling may increase the risk of heart disease, says Dr. Shah. There are many hypotheses. For instance, the rapid changes in body weight can add extra stress to the heart, may lead to vascular dysfunction, or lead to more inflammatory fatty tissue development, he says.

Its also possible that rapid changes in weight could be caused by other medical conditions like cancers, infections, or inflammatory disorders, which could add further stress if a person already has an underlying heart condition, says Shah.

The findings here dont mean that people should abandon all efforts to achieve their healthy weight, says Shah. There are plenty of benefits of weight loss, and people should still strive to find ways they can successfully have sustainable weight loss, he says.

Obesity can lead to several serious comorbidities, includinghigh blood pressure, high cholesterol, and type 2 diabetes, that can worsen your overall heart disease risk, he points out.

It is also very difficult to make many conclusions based on one study alone. We need more data to better understand the magnitude of BMI variability that is most concerning, he says.

Its also worth noting that a much higher proportion of males than females participated in the veterans cohort, and there may have been other risks or contributing factors that the researchers didnt account for that could have led to the findings, says Shah.

This study didnt look at people on GLP-1s. The participants had BMI changes that were not caused by medications, and so this question cant be answered from this data, says Almuwaqqat.

The use of GLP-1 is generally associated with cardiovascular risk reduction, and the impact of weight fluctuations is not clear among these individuals, he says.

GLP-1 medications have several benefits when they are prescribed and taken appropriately, says Shah. At the end of the day it is a benefit-to-risk evaluation that is very specific to the patient. Patients should discuss with their healthcare provider about what is right for them, he says.

The rest is here:
Weight Cycling Increases the Risk of Heart Attack and Stroke - Everyday Health

Read More..

People are drinking a blended oat concoction in the morning, and claiming incredible weight loss results.

The world of diet fads is unfortunately quite vast. From arsenic weight loss pills of the mid-18th century, to the Special K diet of the early aughts, to the media-induced eating disorder culture of today, dieting trends have always been questionable, as they tend to promise fast results and encourage unrealistic expectations. One of these TikTok-viral weight loss fads is cheekily called "Oatzempic."

Article continues below advertisement

Intrigued by the Oatzempic drink's suspicious promise of 40 pounds of weight loss in just two months, we spoke exclusively with Tracy Lockwood Beckerman, registered dietitian and author of The Better Period Food Solution, who gave us some insight into the legitimacy, safety, science, and ethics behind this new internet diet trend.

Article continues below advertisement

The Oatzempic recipe is easy and boasts a minimal ingredient list. Simply add half a cup of oats, juice from half a lime, and a cup of water to a blender. Once blended, just drink up in the morning on an empty stomach, as detailed by TikTok user Adrienne Elaine Chavez. (This is basically how you make homemade oat milk, but with different proportions and the addition of lime juice.)

While creators like @lustforadventuremom, @withlove.renita, and @roxxv10 have documented their journeys, claiming to have actually seen weight loss results, others, including @glendagax, haven't lost any weight.

Article continues below advertisement

"Any trend that promotes real ingredients from nature is a trend that I get can excited about," Beckerman tells us via email, adding that trying Oatzempic "may catapult someone into going grocery shopping more or even making healthier choices throughout the day."

Still, Beckerman offers plenty of concerns and eye rolls about Oatzempic.

"Any weight loss claim with specific pounds and timelines definitely has gaping holes in it," she says. "This smoothie is merely real ingredients that offer up soluble fiber, coming from the oats, and hydration, which can allow someone to maintain fullness for an elongated period of time. That fullness can lead to someone eating less at their next meal which can potentially lead to weight loss."

Article continues below advertisement

Med-peds doc, Dr. Tommy Martin, MD, has spoken about Oatzempic on his TikTok page. He agrees that substituting a traditional fatty breakfast with Oatzempic may help people lose fat and create a calorie deficit, but overall, he has a take similar to Beckerman's.

"Oatmeal helps with satiety, or helps us to stay full throughout the day and leads to snacking less later on in the day as well," he said in a March 2024 video. Additionally, Dr. Martin stated that "the fiber in the oatmeal and the increased water likely is helping [people] to have more regular bowel movements."

Article continues below advertisement

Overall, if people want to hop on the TikTok trend with healthy and realistic intentions, Beckerman doesn't see a major issue with it.

"If someone wants to jump on this smoothie as a means to integrate some belly-filling fiber, vitamin C, hydration, and B vitamins, there is no harm in doing so. Their agenda for integrating the smoothie into their lifestyle would have to be to add some real ingredients with real benefits; if they see some weight loss from eating this way, that is merely a bonus," she maintains. "However, it needs to be integrated in a diet that is filled with mostly plants, lean proteins, whole grains and healthy fats in order to be done safely and wisely."

Of course, we always recommend speaking with your own physician before making any major dietary changes.

Article continues below advertisement

Diet fads of the past, present, and future are closely tied to fatphobia, disordered eating, and toxic "thinspiration" culture. Does the Master Cleanse which involves downing six to 12 glasses of a lemonade, cayenne pepper, and maple syrup concoction a day, plus herbal laxatives sound healthy to you? (Spoiler: It's not.)

Overall, Beckerman believes that these modern diet trends are "capitalizing on the diet and weight loss industry and promising dangerous and falsified results."

"If someone looks at this trend (or any other internet diet fad) with any disordered eating thought patterns and is promised to lose an outrageous amount of weight in a short period of time, it can cause a dieting spiral and dangerous eating patterns to emerge."

All in all, those interested in Oatzempic should proceed with caution, check with a doctor, and analyze their own personal reasons for wanting to try out TikTok's A.M. diet trend.

Visit link:
"Oat Zempic" Drink: An RD Weighs In on the Weight Loss Trend - Green Matters

Read More..

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

See the rest here:
'I'm an Obesity Medicine Specialist Who Has Been Studying Weight Loss for 30+ YearsThis Is the Afternoon Snack I ... - Gwinnettdailypost.com

Read More..

Summary

Scott Wern from the 90 Day Fianc franchise has undergone a significant transformation after an impressive weight-loss journey. Despite being somewhat unpopular on TV, the 53-year-old Florida native has garnered a dedicated fan base who supports him despite his controversial decisions. In his appearance on 90 Day Fianc: Love In Paradise, Scott dated Pedro Jimenos mom, Lidia Morel. However, their relationship was short-lived as Scott soon began dating his much younger ex-girlfriend. His actions annoyed many viewers, which made him a 90 Day Fianc franchise villain, leading him to lose his job.

In 2023, Scott returned to The Family Chantel. He started dating Lidia again, which made Pedro angry. Scott and Pedro got into a physical fight at the gym, and eventually, Scott broke up with Lidia. He faced a lot of social media hate, but he didnt let it affect his fitness journey. Over time, Scott has been more active on social media, and he seems happier than ever. He has been flaunting his happiness, and there are rumors about him starting a new romance with Amanda Wilhelm, a former 90 Day Fianc franchise star.

Like most reality TV stars, Scott has shared throwback photos to discuss his past. In March 2024, he posted a picture of himself from over a decade ago. He talked about his physique and discussed how much he used to weigh.

Scott wrote, I was about 280 with a 42 waist in 2013.

He used a laughing emoji to highlight that he was overweight at the time. The 90 Day Fianc franchise alum looked happy in the throwback photo and seemed buff. Scott has likely been lifting weights for over ten years, making it a part of his lifestyle.

In January 2023, Scott discussed his latest weight loss milestone on social media. He posted a photo of himself looking happier, healthier, and handsome. Scott wrote, 220 lbs today, telling his Team Scotty that he had lost 55 pounds over the years. Scott sported a black shirt to accentuate his muscular body. He wore skin-fit jeans and seemed excited to achieve his weight-loss goal. Fans told the 90 Day Fianc franchise alum that they were proud of him. A social media user commented, you got this I am beyond happy for you!!

Another wrote, stunning physique brah. keep it up.

Scott recently shared a close-up picture of his face, showing how much he has transformed since 2013. He posted an Instagram story comparing his old self to his new one. On the left side, Scott posted a photo of himself wearing a white shirt with a black bow. He had a wider jaw, a bigger face, and heavier cheekbones. On the right side, Scott shared a selfie from his car. He wore a sporty t-shirt and flaunted his chiseled face with a sharp jawline.

The former 90 Day Fianc franchise star titled his story, 275 to 225lbs.

Like most 90 Day Fianc cast members who post about their fitness, Scott has shared his fitness goals with fans. He has revealed that he still has a long way to go to become his ideal self. In 2024, Scott posted an Instagram story with a picture of himself standing on a weight scale. He confidently showed that he was 225.6 pounds and much healthier. He titled the post, my goal is 215, letting his Instagram followers know he still has to lose over 10 pounds. Scott also admitted his other goal is to achieve 12% body fat.

Cast members in their 50s, like Big Ed, Angela Deem, and Gino Palazzolo, look on par with their age. However, Scott still seems in his 40s despite being over 53 years old. The former 90 Day Fianc franchise cast member has worked hard to maintain his youthful looks and toned physique. He has maintained a good physique by focusing on his fitness. In February 2024, Scott shared videos of himself working out at the gym. He showed fans a few of his exercises, giving them useful tips on maintaining a toned upper body, bigger arms, and wider back.

Scott titled his post tips on bicep preacher and rear deltoids, adding that its good food for thought and muscles. He looked incredible in the videos and knew what he was doing. Over 2500 people liked Scotts post, and many applauded him for his remarkable physique. A social media user commented, Id like to see more of this Scott, thanking Scott and encouraging him to make a new account focused on fitness.

Another user wrote, I can watch you work out all the time, pledging their allegiance to Team Scott.

Over the months, many 90 Day Fianc franchise stars have lost weight. However, not all of them have achieved a muscular body like Scott. Since the Florida native is into fitness, he has put a lot of effort into doing more than just dropping a few pounds. He has gained strength by lifting weights and doing functional training. In February 2024, Scott posted a video of himself training the triceps. He was in fantastic shape and easily carried four plates while doing the triceps bench dips.

He titled the post, strip !!!!! great tricep superset, flaunting his strength.

Scott puts a lot of effort into his training routine and has kept himself strong at 53. Therefore, many fans support him on social media and appreciate his passion for fitness. In Scotts recent post, nearly 3k people applauded him for demonstrating exceptional strength. A social media user wrote, thats some good old school stuff, to praise the reality TV star. Another user commented, holy s**t thats cool as hell, letting him know that his smile after he completed the set was awesome. Scott may be a controversial 90 Day Fianc star, but hes genuine about his wellness.

90 Day Fianc is now streaming on Discovery+.

Source: Scott Wern/Instagram, Scott Wern/Instagram, Scott Wern/Instagram, Scott Wern/Instagram

90 Day Fiance is a reality TV series that follows the trials and tribulations of Non-U.S. citizens who travel from abroad each season to meet their potential spouses utilizing a K-1 visa. This three-month visa gives the pair 90 days to determine whether or not their romantic and life goals are aligned before they're forced to return home unmarried. Drama and tension unfold as the couples navigate the tricky dynamics of international marriage.

Excerpt from:
90 Day Fianc: Scott Wern's Face Is Changing After Extraordinary Weight Loss Milestone (See Transformation In ... - Screen Rant

Read More..

Contact Us Today

Page 61«..1020..60616263..7080..»

Home » Page 61